Clinical trials: Vascular Diseases
Severe Dyspnea, CAPD
BIOmarkers of Dyspnea IN Emergency Room
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine…
- Conditions
- Severe Dyspnea, CAPD, AE COPD, Acute Heart Failure
- Trial name
- BIODINER (NCT01227317)
- Testing
- Prognostic value of Biomarkers
- Where
- France
- Volunteers
- 444 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 23 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Coronary Artery Disease, Coronary Arteriosclerosis
Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium
The purpose of this research study is to determine if the transplant of a combination of stem cells, obtained from the bone marrow of the same patient, is effective for utilization and rescue of infarcted myocardium.
- Conditions
- Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
- Trial name
- NCT00548613
- Testing
- MESENDO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- TCA Cellular Therapy
ST-elevation Myocardial Infarction
MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
A prospective, randomized, controlled multi-site feasibility trial to assess the potential role of the IMPELLA® 2.5 System in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI)
- Trial name
- MINI-AMI (NCT01319760)
- Testing
- Impella 2.5 support, Standard of care (Control)
- Volunteers
- 5 people
- Sponsor
- Abiomed Inc.
Pulmonary Hypertension
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH.
- Trial name
- NCT00325403
- Testing
- Oral treprostinil (UT-15C) Sustained Release Tablets
- Where
- 77 sites in United States, Austria and 11 more
- Volunteers
- 349 people
- Sponsor
- United Therapeutics
Myocardial Infarction
Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
- Trial name
- NCT00883727
- Testing
- Stem cell, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
Acute Coronary Syndrome
Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e.
- Trial name
- EPICOR ASIA (NCT01361386)
- Where
- 108 sites in China, India and 5 more
- Volunteers
- 13,011 people
- Sponsor
- AstraZeneca
Coronary Artery Stenosis
Kidney Damage in Patients With Normal eGFR
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR.
- Trial name
- NCT01137786
- Testing
- Non ionic contrast media comparator
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Bracco Diagnostics, Inc
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595673
- Testing
- PB127 for injectable suspension
- Where
- 19 sites in United States
- Volunteers
- 428 people
- Sponsor
- Point Biomedical
Blood Clots, Vascular Disease
Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter
Assess the functionality of the Versus Catheter for catheter-directed thrombolysis of pulmonary blood clots, including advanced imaging assessment.
- Conditions
- Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases
- Trial name
- NCT06975969
- Testing
- Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter
- Where
- United States
- Sponsor
- Liquet Medical Inc.
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Aortic Dissection
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.
- Trial name
- ARISE III (NCT06827990)
- Testing
- GORE® Ascending Stent Graft (ASG device)
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- W.L.Gore & Associates
Varicose Veins
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
The purpose of this study is to evaluate pain the patient experienced following treatment of varicose veins with Varithena® compared to radiofrequency ablation.
- Trial name
- COMFORT (NCT02462720)
- Testing
- Varithena®, Radiofrequency ablation
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Boston Scientific Corporation
Diabetic Foot Ulcer, Diabetic Foot
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
- Conditions
- Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic
- Trial name
- CAMPAIGN (NCT06600724)
- Testing
- Standard of Care, EPIEFFECT, EPIXPRESS
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- MiMedx Group, Inc.
Intracranial Aneurysm
Enterprise Stent Aneurysm Treatment (ESAT) Study - France
The purpose of this study is to evaluate the morbidity, mortality, and efficacy of use of the Enterprise(TM) stent for the treatment of (ruptured or non-ruptured) intracranial aneurysms.
- Trial name
- ESAT (NCT00879580)
- Where
- 14 sites in France
- Volunteers
- 133 people
- Sponsor
- Codman & Shurtleff
Myocardial Infarction, Heart Failure, Congestive
Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial
To assess the efficacy and safety of MyoCell therapy on myocardial function in congestive heart failure patients, post-myocardial infarction
- Trial name
- NCT00375817
- Testing
- Myoblasts injection with MyoCath catheter
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bioheart, Inc.
Urticaria Chronic
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
- Trial name
- NCT06736262
- Testing
- Briquilimab
- Where
- 19 sites in United States, Germany
- Volunteers
- 67 people
- Sponsor
- Jasper Therapeutics, Inc.
Pulmonary Embolism
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Phase II trial of TS23
- Trial name
- NAIL-IT (NCT05408546)
- Testing
- TS23
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Translational Sciences, Inc.
Myocardial Ischaemia, Coronary Artery Disease
Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease
The purpose of this study is to determine whether treatment with 40mg of Rosuvastatin for 8 weeks will reduce the number of episodes of myocardial ischaemia suffered in subjects with coronary artery disease.
- Trial name
- NCT00657527
- Testing
- Rosuvastatin, Cholesterol lowering diet
- Volunteers
- 280 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
- Trial name
- CLEAR Wisdom (NCT02991118)
- Testing
- bempedoic acid
- Where
- 2 sites in United States
- Volunteers
- 779 people
- Sponsor
- Esperion Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.